These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24374365)

  • 21. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand.
    Celentano DD; Beyrer C; Natpratan C; Eiumtrakul S; Sussman L; Renzullo PO; Khamboonruang C; Nelson KE
    AIDS; 1995 Sep; 9(9):1079-83. PubMed ID: 8527082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.
    Thongcharoen P; Suriyanon V; Paris RM; Khamboonruang C; de Souza MS; Ratto-Kim S; Karnasuta C; Polonis VR; Baglyos L; Habib RE; Gurunathan S; Barnett S; Brown AE; Birx DL; McNeil JG; Kim JH;
    J Acquir Immune Defic Syndr; 2007 Sep; 46(1):48-55. PubMed ID: 17909315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials.
    Gilbert PB; Chiu YL; Allen M; Lawrence DN; Chapdu C; Israel H; Holman D; Keefer MC; Wolff M; Frey SE;
    Vaccine; 2003 Jun; 21(21-22):2933-47. PubMed ID: 12798637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
    Laher F; Moodie Z; Cohen KW; Grunenberg N; Bekker LG; Allen M; Frahm N; Yates NL; Morris L; Malahleha M; Mngadi K; Daniels B; Innes C; Saunders K; Grant S; Yu C; Gilbert PB; Phogat S; DiazGranados CA; Koutsoukos M; Van Der Meeren O; Bentley C; Mkhize NN; Pensiero MN; Mehra VL; Kublin JG; Corey L; Montefiori DC; Gray GE; McElrath MJ; Tomaras GD
    PLoS Med; 2020 Feb; 17(2):e1003038. PubMed ID: 32092060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.
    Belshe RB; Graham BS; Keefer MC; Gorse GJ; Wright P; Dolin R; Matthews T; Weinhold K; Bolognesi DP; Sposto R
    JAMA; 1994 Aug; 272(6):475-80. PubMed ID: 7913731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The HVTN503/Phambili HIV vaccine trial: a comparison of younger and older participants.
    Volk JE; Hessol NA; Gray GE; Kublin JG; Churchyard GJ; Mlisana K; Nchabeleng M; Buchbinder SP; Bekker LG
    Int J STD AIDS; 2014 Apr; 25(5):332-40. PubMed ID: 24104693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.
    Keefer MC; Gilmour J; Hayes P; Gill D; Kopycinski J; Cheeseman H; Cashin-Cox M; Naarding M; Clark L; Fernandez N; Bunce CA; Hay CM; Welsh S; Komaroff W; Hachaambwa L; Tarragona-Fiol T; Sayeed E; Zachariah D; Ackland J; Loughran K; Barin B; Cormier E; Cox JH; Fast P; Excler JL
    PLoS One; 2012; 7(8):e41936. PubMed ID: 22870265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses.
    Choi E; Michalski CJ; Choo SH; Kim GN; Banasikowska E; Lee S; Wu K; An HY; Mills A; Schneider S; Bredeek UF; Coulston DR; Ding S; Finzi A; Tian M; Klein K; Arts EJ; Mann JF; Gao Y; Kang CY
    Retrovirology; 2016 Nov; 13(1):82. PubMed ID: 27894306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.
    Moodie Z; Metch B; Bekker LG; Churchyard G; Nchabeleng M; Mlisana K; Laher F; Roux S; Mngadi K; Innes C; Mathebula M; Allen M; Bentley C; Gilbert PB; Robertson M; Kublin J; Corey L; Gray GE
    PLoS One; 2015; 10(9):e0137666. PubMed ID: 26368824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
    Adis International Ltd
    Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers.
    Van Braeckel E; Bourguignon P; Koutsoukos M; Clement F; Janssens M; Carletti I; Collard A; Demoitié MA; Voss G; Leroux-Roels G; McNally L
    Clin Infect Dis; 2011 Feb; 52(4):522-31. PubMed ID: 21208909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benign ethnic neutropenia in a South African population, and its association with HIV acquisition and adverse event reporting in an HIV vaccine clinical trial.
    Mpofu R; Otwombe K; Mlisana K; Nchabeleng M; Allen M; Kublin J; McElrath MJ; Bekker LG; Churchyard G; Gray G; Laher F
    PLoS One; 2021; 16(1):e0241708. PubMed ID: 33481787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction and maintenance of bi-functional (IFN-γ + IL-2+ and IL-2+ TNF-α+) T cell responses by DNA prime MVA boosted subtype C prophylactic vaccine tested in a Phase I trial in India.
    Munusamy Ponnan S; Pattabiram S; Thiruvengadam K; Goyal R; Singla N; Mukherjee J; Chatrath S; Bergin P; T Kopycinski J; Gilmour J; Kumar S; Muthu M; Subramaniam S; Swaminathan S; Prasad Tripathy S; Luke HE
    PLoS One; 2019; 14(3):e0213911. PubMed ID: 30921340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults.
    Durier C; Launay O; Meiffrédy V; Saïdi Y; Salmon D; Lévy Y; Guillet JG; Pialoux G; Aboulker JP
    AIDS; 2006 Apr; 20(7):1039-49. PubMed ID: 16603857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.
    O'Connell RJ; Excler JL; Polonis VR; Ratto-Kim S; Cox J; Jagodzinski LL; Liu M; Wieczorek L; McNeil JG; El-Habib R; Michael NL; Gilliam BL; Paris R; VanCott TC; Tomaras GD; Birx DL; Robb ML; Kim JH
    J Infect Dis; 2016 Jun; 213(12):1946-54. PubMed ID: 26908741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults.
    Wecker M; Gilbert P; Russell N; Hural J; Allen M; Pensiero M; Chulay J; Chiu YL; Abdool Karim SS; Burke DS; ;
    Clin Vaccine Immunol; 2012 Oct; 19(10):1651-60. PubMed ID: 22914365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.
    Vasan S; Schlesinger SJ; Chen Z; Hurley A; Lombardo A; Than S; Adesanya P; Bunce C; Boaz M; Boyle R; Sayeed E; Clark L; Dugin D; Boente-Carrera M; Schmidt C; Fang Q; LeiBa ; Huang Y; Zaharatos GJ; Gardiner DF; Caskey M; Seamons L; Ho M; Dally L; Smith C; Cox J; Gill D; Gilmour J; Keefer MC; Fast P; Ho DD
    PLoS One; 2010 Jan; 5(1):e8816. PubMed ID: 20111599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.
    Mpendo J; Mutua G; Nyombayire J; Ingabire R; Nanvubya A; Anzala O; Karita E; Hayes P; Kopycinski J; Dally L; Hannaman D; Egan MA; Eldridge JH; Syvertsen K; Lehrman J; Rasmussen B; Gilmour J; Cox JH; Fast PE; Schmidt C
    PLoS One; 2015; 10(8):e0134287. PubMed ID: 26252526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simulated vaccine efficacy trials to estimate HIV incidence for actual vaccine clinical trials in key populations in Uganda.
    Abaasa A; Nash S; Mayanja Y; Price M; Fast PE; Kamali A; Kaleebu P; Todd J
    Vaccine; 2019 Apr; 37(15):2065-2072. PubMed ID: 30857933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.